-
公开(公告)号：US09474755B2
公开(公告)日：2016-10-25
申请号：US14809020
申请日：2015-07-24
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07D401/10 , C07D403/10 , A61K31/506 , C07D403/06 , C07D403/14 , C07D409/12 , C07D409/14 , A61K38/05 , C07D401/14 , C07D471/08 , C07K5/078
CPC分类号： A61K38/05 , A61K31/155 , A61K31/4985 , A61K31/506 , A61K31/7004 , C07D401/10 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/14 , C07D409/10 , C07D409/12 , C07D409/14 , C07D471/08 , C07K5/06139 , A61K2300/00
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.
-
公开(公告)号：US20150038416A1
公开(公告)日：2015-02-05
申请号：US14296907
申请日：2014-06-05
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07K5/072 , A61K45/06 , A61K31/4245 , C07D413/14 , A61K31/4545 , C07D413/04 , A61K31/4439 , A61K31/4709 , A61K38/05 , C07D277/30 , A61K31/426 , C07D285/08 , A61K31/433 , C07D239/26 , A61K31/505 , C07D271/06
CPC分类号： C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译： 本发明涉及调节胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂，或者作为受体配体包括GLP-1肽GLP-1（7-36）和GLP-1（9-36）或与基于肽的疗法 ，其中A，B，C，Y 1，Y 2，Z，R 1，R 2，R 3，R 3，R 3，R 3， R4，R5，W1，n，p和q如本文所定义。
-
公开(公告)号：US20140336185A1
公开(公告)日：2014-11-13
申请号：US14122176
申请日：2012-05-31
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Thomas Fowler , Andrew Novak , Premji Meghani , Enugurthi Brahmachary , Adam Richard Yeager
IPC分类号： C07C235/38 , C07D307/54 , A61K31/341 , C07D213/80 , A61K31/4406 , C07D211/34 , A61K31/4465 , C07D295/15 , A61K31/5375 , C07D239/26 , A61K31/505 , A61K31/495 , C07D295/24 , A61K31/54 , A61K31/235
CPC分类号： A61K31/4245 , A61K9/0019 , A61K9/0095 , A61K31/155 , A61K31/235 , A61K31/341 , A61K31/4406 , A61K31/4439 , A61K31/4465 , A61K31/4725 , A61K31/495 , A61K31/505 , A61K31/5375 , A61K31/54 , A61K38/22 , A61K38/26 , A61K45/06 , A61K47/20 , A61K47/26 , A61K47/40 , A61K47/6951 , B82Y5/00 , C07C229/14 , C07C233/47 , C07C233/51 , C07C233/81 , C07C233/83 , C07C235/12 , C07C235/38 , C07C235/48 , C07C237/22 , C07C237/36 , C07C237/42 , C07C255/57 , C07C271/28 , C07C275/42 , C07C311/08 , C07C311/13 , C07C311/21 , C07C311/29 , C07C311/48 , C07C317/28 , C07C317/44 , C07C323/62 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07D207/267 , C07D209/08 , C07D211/14 , C07D211/34 , C07D211/62 , C07D213/55 , C07D213/65 , C07D213/79 , C07D213/80 , C07D213/81 , C07D213/82 , C07D215/48 , C07D217/02 , C07D231/12 , C07D233/60 , C07D235/06 , C07D235/12 , C07D235/18 , C07D239/26 , C07D239/28 , C07D239/74 , C07D239/91 , C07D241/42 , C07D241/44 , C07D249/08 , C07D257/04 , C07D261/18 , C07D263/32 , C07D263/34 , C07D263/48 , C07D263/57 , C07D271/06 , C07D271/07 , C07D271/107 , C07D277/30 , C07D277/56 , C07D277/66 , C07D279/12 , C07D295/15 , C07D295/155 , C07D295/205 , C07D295/24 , C07D307/24 , C07D307/54 , C07D307/68 , C07D307/79 , C07D309/06 , C07D309/08 , C07D311/16 , C07D317/68 , C07D333/38 , C07D413/04 , C07D413/12 , C07D417/12 , C08B37/0015 , C08L5/16 , A61K2300/00
摘要： Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP (1-42), PTH (1-34), Glucagon (1-29), GLP-2 (1-33), GLP-1 (7-36), GLP-1 (9-36), oxyntomodulin and exendin variants.
摘要翻译： 结合胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法，其治疗和/或预防用途的方法及其在体外稳定GLP-1受体中用于GLP- 1受体。 某些化合物自身或存在受体配体如GIP（1-42），PTH可能具有作为胰高血糖素受体，GIP受体，GLP-1和GLP-2受体以及PTH受体的调节剂或增效剂的活性 （1-34），胰高血糖素（1-29），GLP-2（1-33），GLP-1（7-36），GLP-1（9-36），胃泌酸调节蛋白和毒蜥外泌肽变体。
-
公开(公告)号：US20130178420A1
公开(公告)日：2013-07-11
申请号：US13712624
申请日：2012-12-12
申请人： RECEPTOS, INC.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07D413/14 , A61K31/4245 , C07D413/10 , A61K31/454 , A61K31/4545 , A61K31/4709 , C07D239/26 , A61K31/505 , C07D413/12 , A61K31/506 , C07D403/12 , C07D403/04 , C07D243/08 , A61K31/551 , A61K38/26 , C07D271/06
CPC分类号： C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译： 本发明涉及调节胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂，或者作为受体配体包括GLP-1肽GLP-1（7-36）和GLP-1（9-36）或与基于肽的疗法 ，其中A，B，C，Y 1，Y 2，Z，R 1，R 2，R 3，R 3，R 3，R 3， R4，R5，W1，n，p和q如本文所定义。
-
公开(公告)号：US20160228450A1
公开(公告)日：2016-08-11
申请号：US14965777
申请日：2015-12-10
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs , Daniel Glynn , Mark Mills
IPC分类号： A61K31/551 , C07D271/06 , A61K31/4245 , C07D413/04 , A61K31/4545 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/454 , C07D271/107 , C07D263/32 , A61K31/421 , C07D277/30 , A61K31/426 , C07D285/12 , A61K31/433 , C07D285/08 , C07D239/26 , A61K31/505 , A61K31/506 , C07D413/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D495/04 , C07D403/04 , C07D401/04 , C07D239/34 , C07D241/08 , A61K31/495 , A61K31/4178 , C07D211/98 , A61K31/4468 , A61K31/445 , C07D211/22 , C07D207/08 , A61K31/402 , C07D243/08 , C07D213/55 , A61K31/44 , C07D241/12 , A61K31/4965 , C07D237/08 , A61K31/50 , C07D253/065 , A61K31/53 , A61K31/501 , A61K31/497 , C07D409/14 , A61K38/26
CPC分类号： A61K31/551 , A61K31/402 , A61K31/4178 , A61K31/421 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/44 , A61K31/4439 , A61K31/445 , A61K31/4468 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/495 , A61K31/4965 , A61K31/497 , A61K31/50 , A61K31/501 , A61K31/505 , A61K31/506 , A61K31/53 , A61K38/26 , C07D207/08 , C07D211/22 , C07D211/98 , C07D213/55 , C07D215/14 , C07D231/12 , C07D237/08 , C07D239/26 , C07D239/34 , C07D239/74 , C07D241/08 , C07D241/12 , C07D243/08 , C07D253/06 , C07D253/065 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/30 , C07D285/08 , C07D285/12 , C07D295/084 , C07D295/135 , C07D401/04 , C07D401/06 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/12 , C07D407/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D471/04 , C07D495/04
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
-
公开(公告)号：US09260427B2
公开(公告)日：2016-02-16
申请号：US14302260
申请日：2014-06-11
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07D403/10 , A61K31/506 , C07D471/04 , C07D403/12 , C07D401/04 , C07D403/04 , C07D239/26 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D271/06 , C07D495/04 , C07D231/12 , C07D233/64 , C07D243/08 , C07D413/14 , C07D417/04
CPC分类号： C07D495/04 , A61K31/155 , A61K31/415 , A61K31/4164 , A61K31/4245 , A61K31/4453 , A61K31/4985 , A61K31/505 , A61K31/506 , A61K31/551 , C07D231/12 , C07D233/64 , C07D237/04 , C07D239/26 , C07D243/08 , C07D271/06 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D471/04
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译： 提供调节胰高血糖素样肽1（GLP-1）受体的化合物及其合成方法及其治疗和/或预防用途的方法。 这些化合物本身可以作为GLP-1受体的调节剂或增效剂，或者可以作为降解素肽如GLP-1（7-36）和GLP-1（9-36），或者基于肽的疗法，例如 艾塞那肽和利拉鲁肽，具有以下通用结构（其中“”表示化合物的R和S形式中的任一者或两者）：其中A，B，C，Y1，Y2，Z，R1，R2，R3，R4，R5 ，W1，n，p和q如本文所定义。
-
公开(公告)号：US09187522B2
公开(公告)日：2015-11-17
申请号：US14296907
申请日：2014-06-05
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： A61K31/33 , C07K5/072 , C07D233/54 , C07D233/60 , C07D401/04 , C07D403/04 , C07D239/26 , C07D239/34 , C07D409/12 , C07D413/04 , C07D241/08 , C07D417/12 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D495/04 , C07D277/24 , C07D285/12 , C07D211/22 , A61K31/4245 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/26 , C07D243/08 , C07D403/12 , C07D413/10 , C07D413/12 , C07D413/14 , A61K45/06 , C07D291/00 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K38/05 , C07D277/30 , C07D285/08
CPC分类号： C07K5/06113 , A61K31/33 , A61K31/4245 , A61K31/426 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/505 , A61K31/506 , A61K31/551 , A61K38/05 , A61K38/26 , A61K45/06 , C07D211/22 , C07D233/54 , C07D233/60 , C07D239/26 , C07D239/34 , C07D241/08 , C07D243/08 , C07D255/02 , C07D263/32 , C07D271/06 , C07D271/107 , C07D277/24 , C07D277/30 , C07D285/08 , C07D285/12 , C07D291/00 , C07D401/04 , C07D403/04 , C07D403/12 , C07D409/12 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12 , C07D495/04
摘要： The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
摘要翻译： 本发明涉及调节胰高血糖素样肽1（GLP-1）受体的化合物，其合成方法及其治疗和/或预防用途的方法。 这些化合物独立地用作GLP-1受体的调节剂或增强剂，或者作为受体配体包括GLP-1肽GLP-1（7-36）和GLP-1（9-36）或与基于肽的疗法 ，其中A，B，C，Y 1，Y 2，Z，R 1，R 2，R 3，R 3，R 3，R 3， R4，R5，W1，n，p和q如本文所定义。
-
公开(公告)号：US20140031290A1
公开(公告)日：2014-01-30
申请号：US13936815
申请日：2013-07-08
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Liming Huang , Junko Tamiya , Mark T. Griffith , Thomas Fowler , Andrew Novak , Michael Knaggs , Premji Meghani
IPC分类号： A61K38/02 , A61K31/24 , A61K45/06 , A61K31/455 , C07D213/82 , C07D333/38 , A61K31/381 , C07D307/68 , A61K31/34 , C07D307/85 , A61K31/343 , C07D261/18 , A61K31/42 , C07D277/62 , A61K31/428 , C07D241/44 , A61K31/498 , C07D295/155 , A61K31/5375 , C07C235/84
CPC分类号： A61K38/02 , A61K31/24 , A61K31/34 , A61K31/343 , A61K31/381 , A61K31/42 , A61K31/428 , A61K31/455 , A61K31/498 , A61K31/5375 , A61K45/06 , C07C233/87 , C07C235/52 , C07C235/84 , C07C237/36 , C07C237/42 , C07C255/57 , C07C275/42 , C07C317/44 , C07D207/44 , C07D211/62 , C07D213/56 , C07D213/82 , C07D215/48 , C07D231/14 , C07D233/90 , C07D241/44 , C07D257/06 , C07D261/18 , C07D261/20 , C07D263/48 , C07D265/30 , C07D277/62 , C07D277/82 , C07D285/14 , C07D295/15 , C07D295/155 , C07D307/66 , C07D307/68 , C07D307/85 , C07D309/08 , C07D317/60 , C07D333/38 , C07D333/70 , C07D471/04
摘要： Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for use in structural analyses of the GLP-1 receptor. Methods of synthesis, methods of therapeutic and/or prophylactic use, and methods of use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor of such compounds are provided.
摘要翻译： 提供了结合胰高血糖素样肽1受体（GLP-1）受体的化合物，包括作为GLP-1受体的调节剂的化合物和能够诱导对受体的稳定作用的化合物，用于GLP的结构分析 -1受体。 提供了合成方法，治疗和/或预防用途的方法，以及用于稳定GLP-1受体体外用于结合这些化合物的GLP-1受体的方法。
-
公开(公告)号：US09598430B2
公开(公告)日：2017-03-21
申请号：US14958513
申请日：2015-12-03
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： C07D403/10 , A61K31/506 , C07D495/04 , C07D403/12 , C07D401/04 , C07D403/04 , C07D239/26 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/12 , C07D271/06 , C07D231/12 , C07D233/64 , C07D243/08 , C07D413/14 , C07D417/04 , C07D471/04 , A61K31/155 , A61K31/415 , A61K31/4164 , A61K31/4245 , A61K31/4453 , A61K31/4985 , A61K31/505 , A61K31/551 , C07D237/04 , C07D401/12 , C07D403/14 , C07D413/10
CPC分类号： C07D495/04 , A61K31/155 , A61K31/415 , A61K31/4164 , A61K31/4245 , A61K31/4453 , A61K31/4985 , A61K31/505 , A61K31/506 , A61K31/551 , C07D231/12 , C07D233/64 , C07D237/04 , C07D239/26 , C07D243/08 , C07D271/06 , C07D401/04 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/04 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/04 , C07D417/12 , C07D471/04
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, Y1, Y2, Z, R1, R2, R3, R4, R5, W1, n, p and q are as defined herein.
-
公开(公告)号：US20160038487A1
公开(公告)日：2016-02-11
申请号：US14809020
申请日：2015-07-24
申请人： Receptos, Inc.
发明人： Marcus F. Boehm , Esther Martinborough , Manisha Moorjani , Junko Tamiya , Liming Huang , Adam R. Yeager , Enugurthi Brahmachary , Thomas Fowler , Andrew Novak , Premji Meghani , Michael Knaggs
IPC分类号： A61K31/506 , A61K38/05 , C07D409/14 , C07D471/08 , C07D403/10 , C07D403/14 , C07D401/14 , C07K5/078 , C07D409/12
CPC分类号： A61K38/05 , A61K31/155 , A61K31/4985 , A61K31/506 , A61K31/7004 , C07D401/10 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/14 , C07D409/10 , C07D409/12 , C07D409/14 , C07D471/08 , C07K5/06139 , A61K2300/00
摘要： Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36), GLP-1(9-36), and oxyntomodulin, or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “” represents either or both the R and S form of the compound): where A, B, C, R1, R2, R3, R4, R5, n, p and q are as defined herein.
摘要翻译： 提供调节胰高血糖素样肽1（GLP-1）受体的化合物及其合成方法及其治疗和/或预防用途的方法。 这些化合物可以单独作为GLP-1受体的调节剂或增效剂，或者可以作为GLP-1（7-36），GLP-1（9-36）和胃泌酸调节蛋白的肠降血糖素肽或基于肽的疗法 ，其具有以下一般结构（其中“”表示化合物的R和S形式中的任一者或两者）：其中A，B，C，R 1，R 2，R 3，R 4，R 5，n， p和q如本文所定义。
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.039 秒)
